淋巴细胞亚群和氧合指数与病毒性肺炎并发ARDS患者预后结局的相关性

Association of lymphocyte subsets and oxygenation index with treatment outcomes of viral pneumonia patients complicated with ARDS

  • 摘要: 目的 分析淋巴细胞亚群、氧合指数(PaO2/FiO2)与病毒性肺炎(VP)并发急性呼吸窘迫综合征(ARDS)患者预后结局的关系。方法 回顾性选取2023年1月-2025年8月VP并发ARDS患者预后结局为死亡的65例患者为死亡组,同期预后结局为存活的65例患者为生存组。收集临床资料,logistic回归分析VP并发ARDS患者预后结局的影响因素,限制性立方样条(RCS)分析CD4+/CD8+、CD19+、CD16+ 56+、PaO2/FiO2水平与患者预后结局的关系。受试者工作特征曲线(ROC)评估CD4+/CD8+、CD19+、CD16+ 56+、PaO2/FiO2单独及联合预测患者预后结局的效能,决策曲线分析(DCA)评估各指标联合预测的临床实用性。结果 logistic回归显示ARDS严重程度(OR=6.406,95%CI:1.746~23.501)、机械通气时间(OR=1.210,95%CI:1.042~1.406)是VP并发ARDS患者预后结局的独立危险因素; CD4+/CD8+(OR=0.042,95%CI:0.005~0.342)、CD19+(OR=0.739,95%CI:0.574~0.952)、CD16+ 56+(OR=0.742,95%CI:0.575~0.956)、PaO2/FiO2(OR=0.976,95%CI:0.958~0.994)是独立保护因素(P<0.05)。RCS分析可知,CD4+/CD8+、CD19+、CD16+ 56+、PaO2/FiO2与VP并发ARDS患者预后结局间呈剂量-效应关系。ROC显示,CD4+/CD8+、CD19+、CD16+ 56+、PaO2/FiO2联合对预后的预测价值较高(AUC=0.900)。DCA显示阈值概率为0.3~0.9,各指标联合评估VP并发ARDS患者预后结局的净收益更高。结论 VP并发ARDS患者CD4+/CD8+、CD19+、CD16+ 56+、PaO2/FiO2与预后结局之间存在剂量-效应关系,上述指标联合预测患者预后结局的价值最高。

     

    Abstract: OBJECTIVE To observe the association of lymphocyte subsets, oxygenation index (partial pressure of arterial oxygen/fraction of inspired oxygen, PaO2/FiO2) with treatment outcomes of the viral pneumonia (VP) patients complicated with acute respiratory distress syndrome (ARDS). METHODS Totally 65 VP patients complicated with ARDS whose treatment outcomes were death were retrospectively chosen as the death group, meanwhile, 65 patients whose treatment outcomes were survival were chosen as the surgical group. The clinical data were collected. Logistic regression analysis was performed for the influencing factors for the treatment outcomes of the VP patients complicated with ARDS. The association of CD4+/CD8+, CD19+, CD16+ 56+ and PaO2/FiO2 with the treatment outcomes was analyzed by restricted cubic spline (RCS). The efficiencies of single and joint detection of CD4+/CD8+, CD19+, CD16+ 56+ and PaO2/FiO2 in prediction of treatment outcomes were assessed by means of receiver operating characteristic (ROC) curves. The clinical practicability of the joint detection of the indexes was evaluated by decision curve analysis (DCA). RESULTS Logistic regression analysis indicated that the severity of ARDS(OR=6.406,95%CI:1.746 to 23.501)and mechanical ventilation duration (OR=1.210,95%CI:1.042 to 1.406) were the independent risk factors for the treatment outcomes of the VP patients complicated with ARDS; CD4+/CD8+(OR=0.042,95%CI:0.005 to 0.342), CD19+(OR=0.739,95%CI:0.574 to 0.952), CD16+ 56+(OR=0.742,95%CI:0.575 to 0.956) and PaO2/FiO2(OR=0.976,95%CI:0.958 to 0.994) were independent protective factors (P<0.05). RCS analysis revealed that there was dose-response relationship between CD4+/CD8+, CD<sup>19+, CD16+ 56+, PaO2/FiO2 and the treatment outcomes of the VP patients complicated with ARDS. ROC analysis showed that the joint detection of CD4+/CD8+, CD19+, CD16+ 56+ and PaO2/FiO2 had high value in prediction of treatment outcomes(AUC=0.900). DCA indicated that the probability of threshold value was 0.3 to 0.9, and the joint detection of the indexes had higher net profit in assessment of the treatment outcomes of the VP patients complicated with ARDS. CONCLUSIONS There is dose-response relationship between CD4+/CD8+, CD19+, CD16+ 56+, PaO2/FiO2 and the treatment outcomes of the VP patients complicated with ARDS, and the value of the joint detection of the above indexes is highest in prediction of treatment outcomes.

     

/

返回文章
返回